Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naomi B Haas

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Urologic Oncology|October 21, 2017
Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapiesPearl Subramanian, Naomi B Haas
Current Oncology Reports|September 4, 2008
Adjuvant therapy for renal cell carcinomaNaomi B Haas, Robert Uzzo
Current Treatment Options in Oncology|August 23, 2007
Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancerNaomi B Haas, Robert G Uzzo
The Oncologist|June 28, 2014
Adjuvant therapy for renal cell carcinoma: past, present, and futureSumanta K Pal, Naomi B Haas
Urologic Oncology|September 11, 2007
Targeted therapies for kidney cancer in urologic practiceNaomi B Haas, Robert G Uzzo
Advances in Chronic Kidney Disease|December 24, 2013
Hereditary kidney cancer syndromesNaomi B Haas, Katherine L Nathanson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2018
Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?Naomi B Haas, Robert G Uzzo
Current Urology Reports|January 24, 2007
Adjuvant therapy for high-risk renal cell carcinoma patientsDavid A Kunkle, Naomi B Haas, Robert G Uzzo
Hematology/Oncology Clinics of North America|July 19, 2011
Adjuvant and neoadjuvant therapies in high-risk renal cell carcinomaMarc C Smaldone, Chunkit Fung, Robert G Uzzo, et al.
Cancer|February 19, 2008
Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancerRobert G Uzzo, Naomi B Haas, Paul L Crispen, et al.
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Urologic Oncology|October 21, 2017
Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapiesPearl Subramanian, Naomi B Haas
Current Oncology Reports|September 4, 2008
Adjuvant therapy for renal cell carcinomaNaomi B Haas, Robert Uzzo
Current Treatment Options in Oncology|August 23, 2007
Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancerNaomi B Haas, Robert G Uzzo
The Oncologist|June 28, 2014
Adjuvant therapy for renal cell carcinoma: past, present, and futureSumanta K Pal, Naomi B Haas
Urologic Oncology|September 11, 2007
Targeted therapies for kidney cancer in urologic practiceNaomi B Haas, Robert G Uzzo
Advances in Chronic Kidney Disease|December 24, 2013
Hereditary kidney cancer syndromesNaomi B Haas, Katherine L Nathanson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2018
Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?Naomi B Haas, Robert G Uzzo
Current Urology Reports|January 24, 2007
Adjuvant therapy for high-risk renal cell carcinoma patientsDavid A Kunkle, Naomi B Haas, Robert G Uzzo
Hematology/Oncology Clinics of North America|July 19, 2011
Adjuvant and neoadjuvant therapies in high-risk renal cell carcinomaMarc C Smaldone, Chunkit Fung, Robert G Uzzo, et al.
Cancer|February 19, 2008
Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancerRobert G Uzzo, Naomi B Haas, Paul L Crispen, et al.
Pageof 11